Literature DB >> 17997791

Abnormalities of visual-evoked potentials and pupillary light reflexes in a family with autosomal dominant occult macular dystrophy.

Takashi Okuno, Hidehiro Oku, Mineo Kondo, Yozo Miyake, Jun Sugasawa, Takashi Utsumi, Tsunehiko Ikeda.   

Abstract

Occult macular dystrophy (OMD) is an unusual inherited or sporadic macular dystrophy characterized by an essentially normal appearing ocular fundus and normal ocular circulation determined by fluorescein angiography but with a progressive decrease of visual acuity. We present a family with OMD who have a delay in the implicit times of both the visual-evoked potentials and the pupillary light reflexes. Because these delays are usually indicative of optic nerve disorders, deciding on a diagnosis between OMD and optic nerve disorder should be done carefully. We are not aware of any studies that have reported these findings in patients with OMD.

Entities:  

Mesh:

Year:  2007        PMID: 17997791     DOI: 10.1111/j.1442-9071.2007.01589.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  3 in total

1.  Elderly case of pseudo-unilateral occult macular dystrophy with Arg45Trp mutation in RP1L1 gene.

Authors:  Takashi Okuno; Takaaki Hayashi; Jun Sugasawa; Hidehiro Oku; Hisashi Yamada; Hiroshi Tsuneoka; Tsunehiko Ikeda
Journal:  Doc Ophthalmol       Date:  2013-04-26       Impact factor: 2.379

2.  Pattern-reversal visual-evoked potential in patients with occult macular dystrophy.

Authors:  Gen Hanazono; Hisao Ohde; Kei Shinoda; Kazushige Tsunoda; Kazuo Tsubota; Yozo Miyake
Journal:  Clin Ophthalmol       Date:  2010-12-10

3.  A new mutation in the RP1L1 gene in a patient with occult macular dystrophy associated with a depolarizing pattern of focal macular electroretinograms.

Authors:  Takenori Kabuto; Hisatomo Takahashi; Yoko Goto-Fukuura; Tsutomu Igarashi; Masakazu Akahori; Shuhei Kameya; Takeshi Iwata; Atsushi Mizota; Kunihiko Yamaki; Yozo Miyake; Hiroshi Takahashi
Journal:  Mol Vis       Date:  2012-04-24       Impact factor: 2.367

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.